{"id":"sc-methylnaltrexone","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1186579","moleculeType":"Small molecule","molecularWeight":"356.44"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the action of opioids in the gastrointestinal tract, SC Methylnaltrexone reduces the constipating effects of opioids without affecting their analgesic effects. This allows patients to maintain their opioid therapy while minimizing gastrointestinal side effects.","oneSentence":"SC Methylnaltrexone is a peripherally acting mu-opioid receptor antagonist that blocks the action of opioids in the gastrointestinal tract.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:37.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of opioid-induced constipation in adult patients with advanced illness who have not responded to maximum doses of naloxegol or have a medical contraindication to naloxegol"}]},"trialDetails":[{"nctId":"NCT06162377","phase":"PHASE4","title":"Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A \"Window of Opportunity\" Pilot Study.","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-10","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":25},{"nctId":"NCT01367535","phase":"PHASE1","title":"Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2006-03","conditions":"Healthy Adults","enrollment":54},{"nctId":"NCT01367600","phase":"PHASE3","title":"Open-Label Treatment Extension of Protocol MNTX 301","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2003-02","conditions":"Terminal Illness","enrollment":27},{"nctId":"NCT01367496","phase":"PHASE1","title":"Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2002-06","conditions":"Healthy Subjects","enrollment":6},{"nctId":"NCT01367509","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-03","conditions":"Renal Impairment","enrollment":32},{"nctId":"NCT01367574","phase":"PHASE2","title":"Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2002-04","conditions":"Bowel Dysfunction","enrollment":39},{"nctId":"NCT01367522","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-03","conditions":"Liver Dysfunction","enrollment":24},{"nctId":"NCT01367613","phase":"PHASE3","title":"Open-Label Treatment Extension of Protocol MNTX 302","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-03","conditions":"Terminal Illness","enrollment":89},{"nctId":"NCT00402038","phase":"PHASE3","title":"Study of Methylnaltrexone (MNTX) for the Relief of Constipation","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-02","conditions":"Advance Illness Patients With OIC","enrollment":134},{"nctId":"NCT00401362","phase":"PHASE3","title":"A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2003-02","conditions":"Advanced Illness Patients With Opioid Induced Constipation","enrollment":154},{"nctId":"NCT00804141","phase":"PHASE3","title":"Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-12-03","conditions":"Constipation","enrollment":1040},{"nctId":"NCT00640146","phase":"PHASE2","title":"Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2007-10-19","conditions":"Opioid-induced Constipation","enrollment":37},{"nctId":"NCT01368562","phase":"NA","title":"Compassionate Use Study of Methylnaltrexone","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2003-01-24","conditions":"Opioid-induced Constipation","enrollment":26},{"nctId":"NCT01596777","phase":"PHASE1","title":"Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects","status":"COMPLETED","sponsor":"University Medicine Greifswald","startDate":"2010-01","conditions":"Intestinal Obstruction","enrollment":15},{"nctId":"NCT01012960","phase":"PHASE4","title":"Opioids and Esophageal Function","status":"COMPLETED","sponsor":"Region Örebro County","startDate":"2009-11","conditions":"Pharyngeal Dysfunction, Esophageal Dysfunction","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SC Methylnaltrexone","genericName":"SC Methylnaltrexone","companyName":"Bausch Health Americas, Inc.","companyId":"bausch-health-americas-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SC Methylnaltrexone is a small molecule medication used to treat opioid-induced constipation in patients with advanced illness. It is administered subcutaneously and has been studied in clinical trials for various conditions, including terminal illness and liver dysfunction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}